Cerebral Palsy
Conditions
Keywords
Erythropoeitin
Brief summary
This study is a retrospective review on the safety and efficacy of repetitive erythropoietin injection in children with cerebral palsy
Detailed description
Cerebral palsy is mostly caused by hypoxic-ischemic encephalopathy from preterm birth, involving inflammatory and apoptotic cellular response. Erythropoietin (EPO) has shown neuroprotective effects via activation of anti-inflammatory, angiogenic, and anti-apoptotic pathways. The safety and feasibility of EPO in children were proven in previous clinical trials. In addition, the efficacy of EPO is actively being investigated and some reports have shown potential benefits in cerebral palsy. To confirm the safety and efficacy of multiple injections with expected effect, retrospective review on medical records was performed.
Interventions
DRUGrecombinant human erythropoietin
Subcutaneous rhEPO injection
Sponsors
Bundang CHA Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Inclusion criteria
* confirmed clinical diagnosis of cerebral palsy based on neuromotor findings, * less than 18 years of age, * received recombinant human erythropoietin (rhEPO) more than once.
Exclusion criteria
* not responding to phone interview or * no functional assessments available.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | interview was performed at an average of 1 year after the completion of rhEPO injections | telephone interview was conducted to collect information of adverse events from all patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Gross Motor Function Measure | The results between the baseline evaluation before rhEPO injection and the last evaluation at an average of 1 year after rhEPO injections were compared | The change of GMFM score before and after rhEPO injections |
Outcome results
None listed